Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Wolfe Research initiates Alpine Immune with Outperform, cites upcoming data

EditorEmilio Ghigini
Published 15/02/2024, 11:38
© Reuters.
ALPN
-

On Thursday, Wolfe Research began coverage on shares of Alpine Immune Sciences (NASDAQ:ALPN), assigning an Outperform rating to the biotechnology company. The research firm anticipates a year filled with significant developments for Alpine Immune Sciences, highlighting the potential of its pivotal candidate, povetacicept.

The firm's conviction in the stock is bolstered by what it sees as a "de-risked mechanism and superior clinical profile" of the company's treatments. Wolfe Research expects pivotal readouts for povetacicept, including longer-term data on the low-dose and an initial look at high-dose data, which are likely to be released around March or April 2024. The firm suggests there is an 85% or higher probability of success (POS) for these upcoming data releases.

Alpine Immune Sciences focuses on the development of innovative treatments for autoimmune and inflammatory diseases and cancer. Povetacicept is a key asset in their pipeline, and the forthcoming data is highly anticipated by both the company and its investors.

The Outperform rating is indicative of Wolfe Research's positive outlook on the stock, reflecting their expectation that Alpine Immune Sciences will perform better than the overall market or its sector in the foreseeable future. The upcoming data readouts are seen as catalysts that could potentially enhance the company's stock value.

Alpine Immune Sciences has not publicly responded to Wolfe Research's coverage initiation and rating at this time. Investors and market watchers will be closely monitoring the company's progress and updates as the expected data release window approaches.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.